Anti-CD19/CD22 CAR T cells in refractory immune thrombocytopenia of paediatric systemic lupus erythematosus.
Engineered immune cells clear dangerous blood clotting complications in children with lupus when standard drugs fail.
This Annals of Rheumatic Diseases letter reports use of bispecific anti-CD19/CD22 CAR T cell therapy in pediatric systemic lupus erythematosus patients with treatment-refractory ITP, demonstrating responses in a condition that carries significant mortality risk when conventional immunosuppression fails. The case series contributes to the rapidly growing literature on CAR-T for autoimmune diseases, extending the approach to a pediatric SLE complication.
What the study was
- Study design
- case_series
- Population
- Pediatric SLE patients with refractory ITP
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Ann Rheum Dis
Why it surfaced
Extends CAR-T cell therapy into pediatric autoimmune disease (pSLE-associated refractory ITP)—a field moving rapidly following Schett et al. adult SLE/SSc reports; high unmet need; published in Annals of Rheumatic Diseases; letter design caps score at 5.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.